Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TARA-002 by Protara Therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
TARA-002 is under clinical development by Protara Therapeutics and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...
Data Insights
Risk adjusted net present value: What is the current valuation of Protara Therapeutics's TARA-002?
TARA-002 is a cell therapy commercialized by Protara Therapeutics, with a leading Phase II program in Non Muscle Invasive Bladder...